KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBT (2016 - 2025)

Historic EBT for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $87.2 million.

  • Charles River Laboratories International's EBT fell 442.89% to $87.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year decrease of 10427.97%. This contributed to the annual value of $93.1 million for FY2024, which is 8398.13% down from last year.
  • Per Charles River Laboratories International's latest filing, its EBT stood at $87.2 million for Q3 2025, which was down 442.89% from $71.4 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's EBT peaked at $244.9 million during Q4 2022, and registered a low of -$216.8 million during Q4 2024.
  • Its 5-year average for EBT is $103.8 million, with a median of $119.7 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 6718.35% in 2022, then tumbled by 20387.39% in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's EBT stood at $163.6 million in 2021, then soared by 49.67% to $244.9 million in 2022, then fell by 14.79% to $208.7 million in 2023, then crashed by 203.87% to -$216.8 million in 2024, then skyrocketed by 140.22% to $87.2 million in 2025.
  • Its last three reported values are $87.2 million in Q3 2025, $71.4 million for Q2 2025, and $36.0 million during Q1 2025.